Innovating Works

IRCCS-BARI

Desconocido
PREFER: Patient Preferences in benefit risk assessments during the drug life cycle Sofia ref. 115966 INSTITUTO TUMORI GIOVANNI PAOLO II participó en un H2020: H2020-JTI-IMI2-2015-05-two-stage The PREFER project will deliver an overview and evaluation of preference elicitation methods to be applied in the entire drug life cycle, i....
2016-10-21 - 2022-05-31 | Financiado
DiaChemo: Point of care microfluidic device for quantification of chemotherapeutic drugs in small body fluid s... INSTITUTO TUMORI GIOVANNI PAOLO II participó en un H2020: H2020-PHC-2014-2015 The decision-making in chemotherapy nowadays depends on standard methods that are liquid chromatography (LC-MS/MS) followed by mass spectrom...
2015-04-13 - 2020-10-31 | Financiado
NANOFACTURING: The Development of Medium and Large Scale Sustainable Manufacturing Process Platforms for Clinicall... INSTITUTO TUMORI GIOVANNI PAOLO II participó en un H2020: H2020-NMP-2014-2015 A number of nanomedicine formulations have enabled, or been shown to hold considerable potential for enabling more effective and less toxic...
2014-12-15 - 2019-01-31 | Financiado
EUROCANPLATFORM: A European Platform for Translational Cancer Research INSTITUTO TUMORI GIOVANNI PAOLO II participó en un FP7: Europe has a number of advantages as regards developing translational cancer research, yet there is no clear European strategy to meet the i...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.